Publications
256 publications
Funding
14 grantsView NIH portfolio on RePORTER ↗
Active
6 grants- MPIHER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancerNCI · 2026–2031 · via NIH RePORTERR01CA309345-01
- PIThe Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug ResponseNCI · 2025–2029 · via NIH RePORTERR01CA296335-02
- PIHER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinomaNCI · 2024–2029 · via NIH RePORTERR01CA288692-03
- MPIProject 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate CancerNCI · 2001–2027 · via NIH RePORTERP50CA092629-25
Completed grants (8)
- MPIRP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial CancerNCI · 2018–2025 · via NIH RePORTER
- MPIDefining mechanisms of resistance to hormonal therapy in breast cancerNCI · 2018–2024 · via NIH RePORTERR01CA234361-05
- PIProject 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesisNCI · 2018–2024 · via NIH RePORTERP01CA221757-05
- PIDevelopment of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutationsNCI · 2018–2024 · via NIH RePORTERR01CA229624-05
- PIDefining the temporal sequence of PI3K pathway mutations in bladder cancerNCI · 2014–2018 · via NIH RePORTERR01CA182587-05
- PITargeting BRAF and MEK in tumors with BRAF and RAS mutations.NCI · 2008–2014 · via NIH RePORTERR01CA127240-05